XEN1101 clinical trials
Also written XEN1101 and Azetukalner.
How each study uses XEN1101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the XEN1101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Xenon Pharmaceuticals Inc. (11) · James Murrough (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test XEN1101, phase 3 first.
- Jan 2027An Open-Label Study of Azetukalner in Major Depressive DisorderPhase 3 · Xenon Pharmaceuticals Inc.
- Apr 2027A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPhase 3 · Xenon Pharmaceuticals Inc.
- May 2027A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Phase 3 · Xenon Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses XEN1101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- An Open-label Study of XEN1101 in EpilepsyEnrolling by invitationPhase 3Xenon Pharmaceuticals Inc.NCT05718817Written as XEN1101
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)RecruitingPhase 3Xenon Pharmaceuticals Inc.NCT05716100Written as XEN1101
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRecruitingPhase 3Xenon Pharmaceuticals Inc.NCT05667142Written as XEN1101
- XEN1101 for Major Depressive DisorderCompletedPhase 2James MurroughNCT04827901Written as XEN1101
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyActive, not recruitingPhase 2Xenon Pharmaceuticals Inc.NCT03796962Written as XEN1101
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07076407Written as Azetukalner
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderActive, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT06775379Written as Azetukalner
- An Open-Label Study of Azetukalner in Major Depressive DisorderActive, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT06922110Written as Azetukalner
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07217860Written as Azetukalner
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07172516Written as Azetukalner
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderCompletedPhase 2Xenon Pharmaceuticals Inc.NCT05376150Written as XEN1101 10 mg
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresCompletedPhase 3Xenon Pharmaceuticals Inc.NCT05614063Written as XEN1101
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- XEN1101 for Major Depressive DisorderNov 6, 2026NCT04827901
Codes
What other systems call XEN1101 · ClinicalTrials.gg INT001423
- MeSH (NLM) C000710655XEN1101One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710655 | XEN1101 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.